| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 1090 |
| 1 | OXALIPLATIN | 295 |
| 2 | FLUOROURACIL | 271 |
| 3 | FLUOROURACIL CREAM, 0.5% | 270 |
| 4 | PACLITAXEL | 270 |
| 5 | CAPECITABINE | 240 |
| 6 | PACLITAXEL (AIBUMIN-BOUND) | 236 |
| 7 | CARBOPLATIN | 219 |
| 8 | TOCILIZUMAB | 204 |
| 9 | PEMBROLIZUMAB | 196 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | IBUPROFEN LYSINE | 29 | 0.0514 |
| 1 | DEXTROSE ANHYDROUS AND SODIUM CHLORIDE | 1 | 0.0294 |
| 2 | RAMUCIRUMAB | 77 | 0.0124 |
| 3 | CALCIUM SENNOSIDES | 2 | 0.0106 |
| 4 | BEVACIZUMAB | 1090 | 0.0089 |
| 5 | 3% SODIUM CHLORIDE | 1 | 0.0088 |
| 6 | LEVOLEUCOVORIN INJECTION | 26 | 0.0087 |
| 7 | AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT) | 1 | 0.0080 |
| 8 | DIMETICONE | 2 | 0.0071 |
| 9 | LEVOLEUCOVORIN | 26 | 0.0070 |
| # | Drug class | Count |
|---|---|---|
| 0 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 1108 |
| 1 | Platinum-based Drug [EPC] | 611 |
| 2 | Nucleoside Metabolic Inhibitor [EPC] | 521 |
| 3 | Corticosteroid [EPC] | 503 |
| 4 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 354 |
| 5 | Microtubule Inhibitor [EPC] | 326 |
| 6 | Kinase Inhibitor [EPC] | 302 |
| 7 | Nonsteroidal Anti-inflammatory Drug [EPC] | 283 |
| 8 | Interleukin-6 Receptor Antagonist [EPC] | 213 |
| 9 | Proton Pump Inhibitor [EPC] | 147 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 77 | 0.0124 |
| 1 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 1108 | 0.0061 |
| 2 | Interferon gamma Blocker [EPC] | 1 | 0.0048 |
| 3 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 3 | 0.0023 |
| 4 | Platinum-based Drug [EPC] | 611 | 0.0023 |
| 5 | Lymphocyte Activation Gene-3 Blocker [EPC] | 1 | 0.0021 |
| 6 | Microtubule Inhibitor [EPC] | 326 | 0.0020 |
| 7 | CD30-directed Immunoconjugate [EPC] | 20 | 0.0020 |
| 8 | Nucleoside Metabolic Inhibitor [EPC] | 521 | 0.0019 |
| 9 | Vitamin K [EPC] | 7 | 0.0017 |